# BioNexus Gene Lab Corp

BioNexus Gene Lab Corp is a public company listed on Nasdaq as BGLC, headquartered in Kuala Lumpur, Malaysia.

## Company overview

- **Legal name:** BioNexus Gene Lab Corp
- **Former names in filing history:** BioNexus Gene Lab Coporation (2019-01-29 to 2020-05-08)
- **Classification:** Public company
- **Industry (SIC):** 8071 — Services-Medical Laboratories
- **Headquarters:** Kuala Lumpur, Malaysia
- **Incorporated in:** WY
- **Fiscal year end:** December 31
- **Ticker:** Nasdaq: BGLC
- **SEC CIK:** 0001737523

## About

BioNexus Gene Lab Corp is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001737523, and its reported industry is Services-Medical Laboratories. In 10-K filed on 2026-04-14, it reported annual revenue of USD 7,424,911; net income of USD -2,984,607; total assets of USD 9,252,784 for the fiscal period ended 2025-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2025 (period ended 2025-12-31)

- **Revenue:** $7.4M (USD 7,424,911)
- **Net income:** -$3.0M (USD -2,984,607)
- **Total assets:** $9.3M (USD 9,252,784)
- **Cash and equivalents:** $2.5M (USD 2,486,383)
- **Operating cash flow:** -$1.8M (USD -1,838,382)
- **Later filings:** Cash and equivalents: shown as originally filed; later filings report different values for the same periods.

### FY2024 (period ended 2024-12-31)

- **Revenue:** $9.5M (USD 9,510,646)
- **Net income:** -$1.6M (USD -1,598,342)
- **Total assets:** $10.4M (USD 10,433,848)
- **Operating cash flow:** -$2.2M (USD -2,234,260)
- **Later filings:** Operating cash flow: shown as originally filed; later filings report different values for the same periods.

### FY2023 (period ended 2023-12-31)

- **Revenue:** $9.8M (USD 9,770,806)
- **Net income:** -$2.6M (USD -2,629,043)
- **Total assets:** $11.4M (USD 11,399,793)
- **Operating cash flow:** -$1.3M (USD -1,301,595)
- **Later filings:** Operating cash flow: shown as originally filed; later filings report different values for the same periods.

### FY2022 (period ended 2022-12-31)

- **Revenue:** $10.9M (USD 10,928,707)
- **Net income:** -$355,966 (USD -355,966)
- **Total assets:** $8.7M (USD 8,740,162)
- **Operating cash flow:** $544,028 (USD 544,028)
- **Later filings:** Operating cash flow: shown as originally filed; later filings report different values for the same periods.

## Recent SEC filings

- Form 8-K — filed 2026-10-07 — period 2026-10-05 — FORM 8-K
- Form 10-Q — filed 2026-08-14 — period 2026-06-30 — FORM 10-Q
- Form 8-K — filed 2026-07-28 — period 2026-07-28 — FORM 8-K
- Form 8-K — filed 2026-06-05 — period 2026-05-29 — FORM 8-K
- Form 10-Q — filed 2026-05-15 — period 2026-03-31 — FORM 10-Q
- Form 10-K — filed 2026-04-14 — period 2025-12-31 — FORM 10-K
- Form 8-K — filed 2026-03-17 — period 2026-03-11 — FORM 8-K
- Form 8-K — filed 2026-02-23 — period 2026-02-23 — FORM 8-K
- Form 8-K — filed 2026-02-03 — period 2026-01-28 — FORM 8-K
- Form 8-K — filed 2025-12-30 — period 2025-12-24 — FORM 8-K
- Form 8-K — filed 2025-12-23 — period 2025-12-19 — FORM 8-K
- Form DEF 14A — filed 2025-12-03 — period 2025-12-24 — DEF 14A

---

Updated: 2026-10-23T06:09:42Z

Canonical page: https://altss.com/profile/bionexus-gene-lab-corp

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology